المؤلفون: Martin J. Edelman, Michal Kubiak, Yanis Boumber, Hossein Borghaei, Usman Ali, Rodion Velichinskii, Sanjeevani Arora, Randy W. Lesh, Pranshu Bansal

المصدر: Advances in Therapy

مصطلحات موضوعية: Oncology, Programmed death 1 (PD-1), medicine.medical_specialty, medicine.medical_treatment, Context (language use), Review, Pembrolizumab, Disease, Tumor mutation burden (TMB), DNA damage response (DDR), B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Neoplastic Syndromes, Hereditary, Neoplasms, Internal medicine, Biomarkers, Tumor, medicine, Humans, Immunologic Factors, Pharmacology (medical), 030304 developmental biology, 0303 health sciences, Brain Neoplasms, business.industry, Melanoma, Cancer, General Medicine, Immunotherapy, medicine.disease, Immune checkpoint, 3. Good health, Cytotoxic T-lymphocyte antigen 4 (CTLA-4), Mismatch repair deficiency (MMR), 030220 oncology & carcinogenesis, Biomarker (medicine), Colorectal Neoplasms, business, Biomarkers, DNA Damage

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b2a8eb65a8fe41304526cd17befcf5
https://doi.org/10.1007/s12325-019-01051-z